These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18191936)

  • 1. Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran.
    Kenne K; Skanberg I; Glinghammar B; Berson A; Pessayre D; Flinois JP; Beaune P; Edebert I; Pohl CD; Carlsson S; Andersson TB
    Toxicol In Vitro; 2008 Apr; 22(3):730-46. PubMed ID: 18191936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures.
    Ainscow EK; Pilling JE; Brown NM; Orme AT; Sullivan M; Hargreaves AC; Cooke EL; Sullivan E; Carlsson S; Andersson TB
    Expert Opin Drug Saf; 2008 Jul; 7(4):351-65. PubMed ID: 18613800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of hepatotoxicity by sanguinarine is associated with oxidation of protein thiols and disturbance of mitochondrial respiration.
    Choy CS; Cheah KP; Chiou HY; Li JS; Liu YH; Yong SF; Chiu WT; Liao JW; Hu CM
    J Appl Toxicol; 2008 Nov; 28(8):945-56. PubMed ID: 18548746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced liver injury in humans: the case of ximelagatran.
    Keisu M; Andersson TB
    Handb Exp Pharmacol; 2010; (196):407-18. PubMed ID: 20020269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity.
    Lundgren H; Martinsson K; Cederbrant K; Jirholt J; Mucs D; Madeyski-Bengtson K; Havarinasab S; Hultman P
    PLoS One; 2017; 12(9):e0184744. PubMed ID: 28934241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure.
    Felser A; Lindinger PW; Schnell D; Kratschmar DV; Odermatt A; Mies S; Jenö P; Krähenbühl S
    Toxicology; 2014 Oct; 324():136-46. PubMed ID: 25108121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran.
    Andersson U; Lindberg J; Wang S; Balasubramanian R; Marcusson-Ståhl M; Hannula M; Zeng C; Juhasz PJ; Kolmert J; Bäckström J; Nord L; Nilsson K; Martin S; Glinghammar B; Cederbrant K; Schuppe-Koistinen I
    Biomarkers; 2009 Dec; 14(8):572-86. PubMed ID: 19780643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes.
    Sergent O; Ekroos K; Lefeuvre-Orfila L; Rissel M; Forsberg GB; Oscarsson J; Andersson TB; Lagadic-Gossmann D
    Toxicol In Vitro; 2009 Oct; 23(7):1305-10. PubMed ID: 19616086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model.
    Edling Y; Sivertsson L; Andersson TB; Porsmyr-Palmertz M; Ingelman-Sundberg M
    Toxicol In Vitro; 2008 Sep; 22(6):1588-94. PubMed ID: 18640260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells.
    Darnell M; Karlsson JE; Owen A; Hidalgo IJ; Li J; Zhang W; Andersson TB
    Drug Metab Dispos; 2010 Mar; 38(3):491-7. PubMed ID: 20023051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model.
    Sjögren E; Bredberg U; Allard E; Arvidsson B; Bergquist J; Andersson TB; Lennernäs H
    Pharm Res; 2010 Apr; 27(4):597-607. PubMed ID: 20140637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
    Clement B; Lopian K
    Drug Metab Dispos; 2003 May; 31(5):645-51. PubMed ID: 12695354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone.
    Felser A; Blum K; Lindinger PW; Bouitbir J; Krähenbühl S
    Toxicol Sci; 2013 Feb; 131(2):480-90. PubMed ID: 23135547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines.
    Mingard C; Paech F; Bouitbir J; Krähenbühl S
    J Appl Toxicol; 2018 Mar; 38(3):418-431. PubMed ID: 29072336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-carotene prevents bile acid-induced cytotoxicity in the rat hepatocyte: Evidence for an antioxidant and anti-apoptotic role of beta-carotene in vitro.
    Gumpricht E; Dahl R; Devereaux MW; Sokol RJ
    Pediatr Res; 2004 May; 55(5):814-21. PubMed ID: 14764912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism for hepato-protective action of Liangxue Huayu Recipe (LHR): blockade of mitochondrial cytochrome c release and caspase activation.
    Jiang ZQ; Yan XJ; Bi L; Chen JP; Zhou Q; Chen WP
    J Ethnopharmacol; 2013 Jul; 148(3):851-60. PubMed ID: 23711831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypochlorous acid-mediated mitochondrial dysfunction and apoptosis in human hepatoma HepG2 and human fetal liver cells: role of mitochondrial permeability transition.
    Whiteman M; Rose P; Siau JL; Cheung NS; Tan GS; Halliwell B; Armstrong JS
    Free Radic Biol Med; 2005 Jun; 38(12):1571-84. PubMed ID: 15917186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melagatran/ximelagatran: market withdrawal.
    Prescrire Int; 2006 Jun; 15(83):108. PubMed ID: 16767816
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives.
    Waldhauser KM; Török M; Ha HR; Thomet U; Konrad D; Brecht K; Follath F; Krähenbühl S
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1413-23. PubMed ID: 16971508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.